Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Patient acceptability of the app using questionnaire provided when patients attend for their 3rd cycle and quantified using a 5-point Likert scale
研究概览
简要总结
This feasibility study will be conducted in order to provide proof of concept for the CanADVICE+® system comprising a smart phone app and a healthcare organization server side application based on Web 2 technologies. The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with metastatic breast cancer
- •Commencing first cycle of Capecitabine
- •Familiar with and own an android smartphone
- •Willing to participate
排除标准
- •Patients <18 years
- •Patients taking part in any other trial containing Capecitabine
- •Chemotherapy-naïve patients
研究组 & 干预措施
Patients eligible for CanADVICE+® (smart phone app)
干预措施: CanADVICE+® (smart phone app) (Device)
结局指标
主要结局
Patient acceptability of the app using questionnaire provided when patients attend for their 3rd cycle and quantified using a 5-point Likert scale
时间窗: 42 days
The app will be used at cycles 1 and 2 of capecitabine (each cycle is 21 days), and acceptability of the app will be measured using a questionnaire when patients attend hospital for their 3rd cycle of capecitabine.
次要结局
- Health care provider's acceptability of the app using questionnaires(48 months)
- Patients' interactivity with the app will be measured using mobile app and web server functions(42 days)